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Abstract
Background: Induction therapy of multiple myeloma patients prior to autologous stem cell transplantation
has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory
drugs. We used flow cytometry to analyze total monocyte and monocyte subset (classical, intermediate and non-
classical monocytes) peripheral blood levels before and following auto-transplantation for a consecutive group of
myeloma patients who had received the presently used induction therapy.
Results: The patients showed normal total monocyte concentrations after induction/stem cell mobilization, but the
concentrations of classical monocytes were increased compared with healthy controls. Melphalan conditioning reduced
the levels of total CD14+ as well as classical and non-classical monocytes, whereas intermediate monocytes were not
affected. Thus, melphalan has a non-random effect on monocyte subsets. Melphalan had a stronger effect on total and
classical monocyte concentrations for those patients who had received induction therapy including immunomodulatory
drugs. Total monocytes and monocyte subset concentrations decreased during the period of pancytopenia,
but monocyte reconstitution occurred before hematopoietic reconstitution. However, the fractions of various
monocyte subsets varied considerably between patients.
Conclusions: The total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma,
but pre- and post-transplant levels of various monocyte subsets show considerable variation between patients.
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Background
Multiple myeloma is usually characterized by prolifera-
tion of abnormal plasma cells in the bone marrow and
secretion of monoclonal immunoglobulin [1–3]. Auto-
logous stem cell transplantation is an established part of
early myeloma-stabilizing treatment [4, 5], and the
patients usually develop a quantitative posttransplant
CD4+ T cell defect that lasts for several months [6]. The
posttransplant innate immune system is less well charac-
terized, but early reconstitution of monocytes with
reduced expression of HLA-DR and CD16 together with
reduced cytokine production has been observed [7, 8],
especially decreased release of proinflammatory cytokines
(e.g. IL-6, TNF-α and IL-1β) [8].
Monocytes constitute up to 10% of total circulating
peripheral blood leukocytes in healthy individuals [9];
they can differentiate into macrophages or dendritic cells
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[10] and may also differentiate in endothelial direction
[11]. Furthermore, immunomodulatory drugs (IMiDs,
e.g. lenalidomide) can induce differentiation towards
dendritic cells with modulation of the cytokine profile,
the transcriptional regulation and the accessory cell
functions [12]. Finally, based on the expression of CD14
(a cell surface co-receptor for lipopolysaccharide) and
CD16 (the low affinity IgG receptor) monocytes are now
divided into classical (CD14bright CD16negative), inter-
mediate (CD14bright CD16dim) and non-classical
(CD14dim CD16bright) monocytes [13–15]. Classical
monocytes constitute 90% of the circulating monocytes
in healthy individuals [13, 15, 16].
Monocytes seem to be involved in the development of
myeloma bone disease [17–20] through the release of
soluble mediators that stimulate osteoclastogenesis, and
the presence of non-classical monocytes may be a poten-
tial marker for increased osteoclast precursors [18, 19].
However, monocytes are also important immunoregula-
tory cells, and they are important for the defense against
complicating infections in myeloma patients [21–23].
Several new drugs have become available during the last
decade for the treatment of multiple myeloma, and no
previous studies have investigated the effects of these
drugs on the levels of circulating monocyte subsets
before and following auto-transplantation. In the present
study, we therefore used a highly standardized method-
ology to characterize peripheral blood levels of mono-
cyte subsets in auto-transplanted myeloma patients
receiving pre-transplant induction treatment based on
proteasome inhibitors and IMiDs.
Results
Myeloma patients show decreased concentrations of
circulating total leukocytes prior to high-dose melphalan
conditioning
We first compared the total leukocyte counts in periph-
eral blood for myeloma patients (Table 1, patients 2–18)
and the healthy controls (12 males and 5 females, me-
dian age 51 years). The patients were tested immediately
before high-dose melphalan conditioning, i.e. after initial
induction treatment (see Table 1) followed by stem cell
mobilization/collection based on cyclophosphamide plus
G-CSF. At this time point they showed significantly
decreased total leukocyte counts compared with the
controls (Fig. 1a, p = 0.004), and patients receiving their
first and second auto-transplantation showed a similar
decrease. The decreased leukocyte counts were seen
with both analytical methods (flow cytometry with
counting beads, measurement by clinical hematology
instrument), and the levels measured by these two
methods were significantly correlated (Pearson cor-
relation coefficient 0.963, p-value 0.0001). The total
leukocyte levels prior to melphalan conditioning showed
no association with age, induction treatment (regimen,
number of cycles), response to induction treatment,
circulating CD34+ cell level at the day of harvesting or
duration of posttransplant neutropenia/cytopenia (data
not shown).
Myeloma patients show normal peripheral blood
concentrations of total monocytes but decreased levels of
classical monocytes prior to high-dose melphalan
The preconditioning peripheral blood concentrations of
total CD14+ monocytes did not differ between the 17
myeloma patients (Table 1, patients 2–18) and 17 healthy
controls (Fig. 1a). However, classical monocyte concentra-
tions were then slightly increased (Fig. 1a, p = 0.01)
whereas we could not detect any significant differences
between patients and controls for intermediate and non-
classical monocytes. The three patients admitted for their
second auto-transplantation showed total monocyte and
monocyte subset concentrations within the range for the
patients admitted for their first transplantation (Fig. 1).
Thus, the effect of mobilization/conditioning on circulat-
ing monocytes is a non-random effect mainly affecting the
classical monocyte subset.
The total monocyte concentrations prior to the condi-
tioning therapy showed no association with age, induction
treatment (regimen, number of cycles), response to induc-
tion treatment, circulating CD34+ cell level at the first day
of harvesting or the duration of posttransplant neutro-
penia/cytopenia (data not shown). The same was true for
classical, intermediate and non-classical monocytes except
that pre-harvesting CD34+ cell levels showed significant
correlations to absolute and relative levels of intermediate
(r = 0.78/p = 0.001 and r = 0.75/p = 0.002, respectively) and
non-classical monocytes (r = 0.63/p = 0.017 and r = 0.61/
p = 0.047, respectively.
Myeloma patients are heterogeneous with regard to the
preconditioning monocyte subset distribution/percentage
in peripheral blood
We first compared the relative levels of circulating total
CD14+ monocytes (percentage of total leukocytes) and
the various monocyte subsets (percentage of total mono-
cytes) for 18 newly diagnosed myeloma patients (Table 1,
patients 1–18) and the 17 healthy controls. The precondi-
tioning percentage of CD14+ monocytes among total leu-
kocytes was increased for the patients; this was expected
since total leukocyte levels were decreased whereas the
monocyte concentration was not significantly altered
before melphalan conditioning (Fig. 1b, p = 0.013).
The preconditioning percentages of the classical, inter-
mediate and non-classical monocyte subsets among
CD14+ monocytes did not differ between patients and
healthy controls (Fig. 1b). However, the variation range
was wider for the patients both for the percentage of
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total CD14+ monocytes and the three monocyte subsets.
Firstly, classical monocytes constituted a majority of the
CD14+ monocytes (corresponding to > 70%) both for the
healthy controls and for all except five patients. We also
observed wide variation ranges for the intermediate and
non-classical monocyte subsets; exceptional patients
showed intermediate monocyte levels exceeding 15%
and non-classical monocytes levels up to 40% of the
total CD14+ monocytes (Fig. 1b). Wide variations were
observed both for patients admitted to their first auto-
transplantation and for the four patients admitted to
their second transplantation. The percentages of total
monocytes and monocyte subsets showed no significant
associations with age, induction treatment, response to
induction treatment, CD34+ cell level at the day of har-
vesting or time until posttransplant neutrophil/platelet
reconstitution (data not shown).
The concentrations of circulating CD14+ monocytes
decrease early after melphalan conditioning
We compared the peripheral blood levels of total leuko-
cytes and CD14+ monocytes before the conditioning
therapy (day − 2) and 2 days later immediately before
the autologous stem cell reinfusion (day 0). Ten patients
Table 1 The characteristics of the myeloma patients included in the study
Patient Aged) M-
component









Pretransplant treatment Number of cycles Neutrophils Thrombocytes
1 60–70 IgG MM Second CVD 4 VGPR 5 2
2 60–70 IgG MM CVD 4 VGPR 171,270 4 1
3 60–70 IgA MM Second CVD 4 VGPR 5 3
4 50–60 IgG MM CVD 5 VGPR 32,180 5 5
5 50–60 IgG MM CVD 5 PR 48,635 2 1
6 30–40 LCD CVD (1), KRD (4) 5 VGPR 70,570 5 3
7 60–70 IgG MM VTD (1), CVD (2) 3 VGPR 218,945 4 2
8 60–70 IgG MM CVD 4 VGPR 90,930 4 4
9 60–70 IgA MM CVD 5 PR 42,285 3 3
10 50–60 IgG MM Second PVD 6 PR 5 4
11 50–60 IgA MM CVD 4 VGPR 32,125 5 4
12 60–70 IgA MM Second VRD 4 VGPR 5 2
13 60–70 LCD-L CVD 4 VGPR 60,410 5 4
14 60–70 IgG MM CVD, VTD, VD (3) 5 VGPR 123,190 6 1
15 60–70 IgG MM VCD 4 PR 37,060 8 5
16 60–70 LCD-K RD 4 VGPR 36,010 4 6
17 50–60 IgA-MM CVD 4 VGPR 132,000 4 5
18 60–70 LCD-L CVD (4 before and 2 after harvesting) 6 VGPR 27,690 5 5
19 50–60 IgG MM Second CVD 4 VGPR 5 3
20 50–60 Amyloid-MM IgG-L CVD (3), VTD (1) 4 185,800 4 2
21 40–50 IgG MM CVD (4 before harvesting), VTD (2 after), RD (2 after) 8 VGPR 56,380 4 6
22 50–60 LCD-L Second CVD 4 PR 7 5
23 50–60 IgG MM Second CVD, VTD, VD (4) 6 PR 5 5
24 50–60 LCD-L CVD 4 VGPR 74,800 3 4
25 60–70 LCD-K Second CVD 4 PR 3 2
Abbreviations: CVD Cyclophosphamide, bortezomib (Velcade®), dexamethasone, LCD Light chain disease type lambda (L) or kappa (K), MM Multiple myeloma, PR
Partial response, RD Lenalidomide (Revlemide®) plus dexamethasone, VGPR Very good partial response, VRD Bortezomib, lenalidomide (Revlemide®),
dexamethasone, VTD Bortezomib (Velcade®), thalidomide, dexamethasone
a) Patients undergoing their second auto-transplantation are indicated; the stem cell graft was the same as for the first transplantation for all these patients
b) The peripheral blood concentration of CD34+ cells on the (first) day of harvesting is given; the level is expressed as × 103 cells/mL
c) Neutropenia was defined as the time from the first day of neutrophil peripheral blood concentration ≤ 0.2 × 109/L until the first of three consecutive days with
neutrophils exceeding 0.2 × 109/L or alternatively the first day with neutrophil counts > 10 × 109/L. The duration of thrombocytopenia was defined as the number
of days from the first day of peripheral blood thrombocyte counts below 20 × 109/L until the first day with thrombocyte count above 20 × 109/L without
thrombocyte transfusion
d) The age of patients are grouped
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were available for this paired comparison (Table 1, pa-
tients 7–9, 11–17), and total leukocyte levels were not
altered 2 days after the melphalan infusion (i.e. immedi-
ately before transplantation, see Fig. 2a). In contrast, the
concentrations of circulating monocytes were signifi-
cantly decreased 2 days after the conditioning, and a
similar decrease was observed when total monocyte
levels were analyzed by clinical hematology instrument(-
data not shown) and when using whole-blood staining
for flow cytometric analysis of CD14+ monocytes (Fig.
2b). A comparable decrease was seen for patients receiv-
ing their first and the second auto-transplantation, but
neutrophil levels were increased for many patients (see
below) so that total leukocyte levels were not signifi-
cantly altered.
We finally compared the levels of circulating neutro-
phils, total lymphocytes and thrombocytes (estimated by
clinical hematology instrument) immediately before and
2 days after melphalan conditioning (Table 1, patients
7–9, 11–17). The neutrophil levels 2 days after melpha-
lan were slightly increased (median level 3.6 versus 4.9 ×
109/L, p = 0.06), whereas lymphocyte (median level 1.0
versus 0.2 × 109/L, p = 0.002) and thrombocyte levels
(median levels 225 versus 177 × 109/L, p = 0.002) were
significantly decreased similar to the monocyte levels.
Melphalan conditioning causes an early decrease in the
percentages of circulating classical and non-classical
monocytes whereas the levels of the intermediate subset
are not altered
We compared the peripheral blood percentages of clas-
sical, intermediate and non-classical monocytes at day − 2
pre-transplant (i.e. before conditioning) and day 0 (i.e. be-
fore stem cell transplantation) for 10 patients (Fig. 2c-e;
Table 1 patients 7–9, 11–17). The concentrations of all
three monocyte subsets were decreased for most patients
2 days after the conditioning, but the difference reached
statistical significance only for the classical (Wilcoxon’s
test for paired samples; p = 0.002) and non-classical sub-
sets (p = 0.0039). Thus, melphalan conditioning has a non-
random early effect on circulating monocyte subsets.
However, we observed a wide variation in the percentage
of the various monocyte subsets among total CD14+
monocytes in preconditioning samples (Fig. 1), and wide
variations persisted after conditioning both for the clas-
sical (variation range 41–93%), intermediate (2–48%) and
non-classical (2–51%) monocyte subsets.
The early effect of melphalan conditioning on monocyte
concentrations differs between patients receiving
induction treatment with and without
immunomodulatory drugs
IMiDs can alter the monocyte phenotype [24], and we there-
fore compared the effect of the melphalan conditioning for
patients receiving induction treatment with or without
IMiDs (i.e. thalidomide, lenalidomide, pomalidomide). A
total of 13 patients were included in this analysis. At
day 0 (the day of transplantation) patients receiving
induction treatment including IMiDs showed decreased
concentrations of circulating total monocytes (median
level 0.0023 × 109/L with range 0.001–0.01 versus
0.0061 × 109/L with range 0.003–0.03; p = 0.045) and
classical monocytes (median 0.0022 × 109/L with range
0.001–0.010 versus 0.0057 × 109/L with range 0.0003–
0.016; p = 0.046) compared with patients receiving in-
duction treatment without these drugs). Furthermore,
the absolute and relative levels of total monocytes and
the various monocyte subsets 2 days after the condi-
tioning therapy (i.e. on day 0, the day of transplant-
ation) showed no association with age, response to
induction treatment or levels of circulating CD34+ cells
at the first day of harvesting (data not shown). Finally,
the day 0 pretransplant levels of circulating neutrophils,
total lymphocytes and thrombocytes did not differ be-
tween patients that had received induction therapy with
and without IMiDs (data not shown). Thus, the IMiDs
seem to have a non-random effect on the various
monocyte subsets that becomes detectable after the
melphalan infusion.
The peripheral blood concentrations of all three
monocyte subsets show a further decrease during the
period of severe neutropenia
We investigated the peripheral blood concentrations of
the three monocyte subsets during the period of severe
neutropenia for 8 myeloma patients (Table 1 patients 13,
14, 16, 17, 21–24); for five of these patients we could
compare the levels immediately before stem cell reinfu-
sion with the levels during severe cytopenia (patients 13,
14, 16, 17, 21). As expected the concentrations of all
three monocyte subsets, especially the classical and
intermediate subsets, decreased to low levels during
cytopenia (Fig. 2). In contrast, the relative levels (i.e.
percentage among total CD14+ monocytes) varied dur-
ing pancytopenia when tested 6–8 days after stem cell
reinfusion. All patients showed < 5% intermediate mono-
cytes, whereas classical monocyte levels varied between
8 and 92% (median 62%) and non-classical monocytes
also showed a considerable variation (median 18%, range
3–57%).
Auto-transplanted myeloma patients show expected early
hematological reconstitution
The levels of circulating total leukocytes, neutrophils
and thrombocytes were measured by clinical hematology
instrument) for all our patients. Neutrophil reconstitu-
tion was defined as the first of 3 days with neutrophils
above 0.2 × 109/L. The median time from first day of
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neutropenia (i.e. first day with neutrophils ≤0.2 × 109/L)
until neutrophil reconstitution was 4 days (range 2–9
days). Furthermore, thrombocyte reconstitution was de-
fined as the first out of three consecutive days with
thrombocyte counts above 20 × 109/L in transfusion-
independent patients. The median duration of
thrombocytopenia (i.e. thrombocyte levels below 20 ×
109/L) was 4 days (range 1–6 days). Finally, time to neu-
trophil/thrombocyte reconstitution did not differ be-
tween patients receiving their first or second auto-
transplantation and showed no significant associations
with preconditioning (i.e. day − 2) or pre-transplant (i.e.
day 0) total monocyte levels.
Auto-transplanted myeloma patients show early
monocyte reconstitution
The absolute levels of total monocytes were followed
daily during the period of early hematological reconstitu-
tion for 24 consecutive patients. The median time from
transplantation until the monocyte levels exceeded the
lower normal limit (0.04 × 109/L) was 10 days; the
median monocyte level was then 0.23 × 109/L (range
0.05–0.78 × 109/L). The neutrophil levels at the first day
of monocyte normalization were generally below the
lower normal limit (median 0.5 × 109/L, range 0.1–3.8 ×
109/L), i.e. for 18 patients the neutrophil levels were still
below the lower normal limit. All patients still had
severe thrombocytopenia (median 29 × 109/L, range 13–
38 × 109/L) at the first day of monocyte normalization.
Finally, there was no significant association between pre-
conditioning or pre-transplant total monocyte levels and
time to normalized circulating monocyte levels, and
monocyte normalization did not differ for patients
receiving induction treatment with or without IMiDs
(data not shown).
We compared the absolute and relative levels of vari-
ous monocyte subsets at day + 10/+ 12 posttransplant
with the corresponding preconditioning levels (day − 2);
paired samples were then available only for eight pa-
tients (Fig. 3; Table 1 patients 14, 16, 17, 21–25). This
posttransplant time point corresponds to the initial neu-
trophil reconstitution, but the neutrophil levels were still
below the lower normal limit for six of the eight patients
(median level 0.7 × 109/L, range 0.2–6.8 × 109/L). The
thrombocyte counts for all patients (median 30 × 109/L,
range 20–52 × 109/L) were also below the lower normal
limit. However, even at this early time point only 10–12
days post-transplant most patients showed normalized
absolute (concentration) and relative (percentage) levels
of total CD14+ monocytes as well as the three monocyte
subsets within the pre-transplant variation range.
One of our collaborating local hospitals only investi-
gated peripheral blood neutrophil but not monocyte
counts at the out-patient evaluations; for this reason
peripheral blood monocyte counts were only available at
later time points for 15 patients. The total monocyte
count (normal range 0.04–1.30 × 109/l) was tested early
after neutrophil and platelet reconstitution, and at this
time point (median time 14 days posttransplant, range
14–16) nine patients showed normal and six patients
showed increased counts (median 0.95 × 109/L, range
0.40–2.1 × 109/l). The total monocyte counts tested at a
later time point (median 30 days posttransplant, range
27–39 days) showed increased levels for a minority of
four patients (median level 0.97 × 109/L, range 0.20–
1.78 × 109/L).
Most patients shows disease stabilization lasting at least
2 years after the first transplantation
The posttransplant observation time for patients receiv-
ing their first auto-transplantation was 27–36months
(median 32months). Five patients had disease progres-
sion less than 2 years post-transplant, one patient was
lost from follow-up and all other patients remained in
plateau phase during follow-up. Progression-free survival
less than 2 years showed no association with precondi-
tion (n = 16) or pretransplant (n = 18) total monocyte or
monocyte subset levels or with posttransplant time to
normalized total monocyte levels (n = 24) (data not
shown).
Discussion
Autologous stem cell transplantation is widely used in
the treatment of younger myeloma patients up to 70
(See figure on previous page.)
Fig. 1 The peripheral blood levels of total leukocytes, total monocytes and monocyte subsets; a comparison between healthy controls and
multiple myeloma patients examined after the initial induction chemotherapy and stem cell harvesting with cyclophosphamide plus G-CSF, i.e.
immediately before conditioning high-dose melphalan therapy (pre-transplant day − 2). (a, UPPER FIGURES) We used flow cytometry to estimate
the concentrations of total circulating leukocytes, total CD14+ monocytes and classical, intermediate and non-classical monocyte subset. The
results for 17 patients (Table 1, patients 2–18) were compared with 17 healthy controls (CTR) individuals. Three of the 17 patients received their
second auto-transplantation. (b, LOWER FIGURES) The percentage of circulating CD14+ monocytes among total leukocytes and the percentages
of classical, intermediate and non-classical monocytes among total CD14+monocytes were estimated. The results for 18 patients (Table 1, patients
1–18) were compared with the 17 healthy individuals. Four patients received their second auto-transplantation. In all the figures, black symbols
represent the levels for patients receiving their first auto-transplantation whereas open symbols represent levels for patients receiving their
second transplantation. The Wilcoxon’s test for paired samples was used for statistical analyses and the p-values for statistically significant
differences are indicated in the figure
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years of age [25]. The pre-transplant conditioning ther-
apy has direct anti-leukemic effects, but previous studies
suggest that immune-mediated anti-myeloma activity
may also contribute to the effect of this therapy [26–28].
The lymphoid reconstitution has been investigated in
previous studies [29], but the monocytes are less well
characterized and for many of the previous studies the
induction treatment included conventional cytotoxic
drugs and not proteasome inhibitors or IMiDs. In our
present study, we investigated the levels of circulating
total monocytes and monocyte subsets in auto-
transplanted myeloma patients. Although our study is
relatively small, we observed that the pre-transplant in-
duction and stem cell mobilization by cyclophosphamide
plus G-CSF seemed to have only a minor effect on the
preconditioning monocyte levels even though the con-
centration of total circulating leukocytes was decreased
compared with the healthy controls.
Our present observations will probably not only depend
on the use of IMiDs and proteasome inhibitors in the in-
duction treatment but on the overall clinical and bio-
logical context of our patients. One should emphasize that
the use of cyclophosphamide in stem cell mobilization will
probably influence our results. The same may be true for
our use of posttransplant G-CSF therapy, e.g. through its
effects on systemic metabolic regulation that influence the
metabolic environment of regenerating hematopoietic and
immunocompetent cells [30]. Furthermore, studies in
healthy donors show that G-CSF has a mobilizing effect
on many different immunocompetent cells, including
monocytes [31, 32]. These effects differ between healthy
donors; they will also influence the levels of immunocom-
petent cells in the stem cell grafts and possibly also out-
come in allotransplant recipients. To the best of our
knowledge it is not known whether similar differences
exist for auto-transplanted myeloma patients, and unfor-
tunately we do not have information about graft levels of
various monocyte subsets for our patients.
We analyzed the total number of monocytes by two
different methodological approaches, i.e. by using a
hemocytometer and by using flow cytometry to estimate
the levels of CD14+ total monocytes. Both these analyses
showed that the preconditioning patient levels did not
differ from healthy controls, whereas the levels 2 days
after the conditioning (i.e. immediately before stem cell
reinfusion) were decreased compared with the precondi-
tioning levels. However, the levels of CD14+ monocytes
were lower than the monocyte levels estimated in the
alternative assays, and this difference is probably due to
a random loss of cells during the washing steps.
Our studies included all except one patient from a de-
fined geographic area and during a defined time period;
for this reason it should be regarded as a population-
based study. We could not investigate all patients at every
time point during the treatment. However, we would
emphasize that this was due to practical reasons such as
transfer of patients to their local hospital or long traveling
distance from their home to the transplantation center; it
was not because of the disease, the treatment or develop-
ment of complications. Leukocyte levels show diurnal var-
iations [33–36], and for this reason we sampled the
patients only in the morning, and shipment of samples or
analysis of cryopreserved cells was not possible due to our
standardized methods for handling of the samples [37].
Our present study showed that the preconditioning
patient levels did not differ from healthy controls, i.e.
the myeloma disease itself, the induction treatment and
the stem cell mobilization by cyclophosphamide plus G-
CSF have only minor effects on monocytes except for a
slight increase of classical monocytes. In contrast, the
melphalan conditioning seemed to have a nonrandom
effect of the monocyte subsets before an early reconsti-
tution of all three subsets was observed. However, it
should be emphasized that there is a wide variation
between patients with regard to the effects of the condi-
tioning therapy. A short duration of this monocytopenia
is also suggested by previous studies [7, 8], but our study
is the first to suggest that this is true also for patients re-
ceiving IMiD- or proteasome inhibitor-based induction
therapy and for different monocyte subsets. Further-
more, the studies by Callander et al. [38] suggest that
even though monocyte levels are normalized at day 100
posttransplant, the levels of total CD14+ and
CD14+CD16low/negative classical monocytes are then asso-
ciated with prolonged progression-free survival after
auto-transplantation. Thus, taken together these studies
show that monocyte reconstitution occurs early (according
to our study very early) after auto-transplantation, but
(See figure on previous page.)
Fig. 2 The peripheral blood concentrations of total leukocytes (a), CD14+ monocytes (b), classical (c), intermediate (d) and non-classical (e)
monocytes in auto-transplanted myeloma patients. We estimated the cell concentrations by flow cytometry. The left parts of each panel show a
comparison of peripheral blood levels before versus 2 days after the conditioning melphalan therapy (day − 2 versus day 0; Table 1, patients 7–9,
12–18). The middle parts show a comparison of levels at the time of transplantation (day 0) versus the levels during the period of severe
posttransplant melphalan-induced pancytopenia with neutrophils < 0.2 × 109/L and thrombocyte transfusion dependency (tested 6–8 days
posttransplant; Table 1, patients 14, 15, 17, 22, 24). The right panel show the comparison of peripheral blood levels during the severe
pancytopenia versus the levels during initial hematopoietic and immunological reconstitution (tested 10–12 days posttransplant with increasing
neutrophils > 0.2 × 109/L and thrombocyte transfusion independence; Table 1 patients 15, 17, 18, 22–24). The Wilcoxon’s test for paired samples
was used for statistical analyses and significant p-values are indicated in the figure (ASCT, autologous stem cell transplantation)
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despite this normalization there is still a relatively wide va-
riation between patients and this heterogeneity in monocyte
(subset) levels seems to persist until day 100 posttransplant
and may even have a prognostic impact. The antimyeloma
effect of posttransplant monocyte targeting may therefore
vary between patients and depend on the monocyte subset
profile. IL6 is regarded as a possible target in multiple
myeloma [39]; monocytes constitute a subset of the bone
marrow stromal cells that are regarded as important regula-
tors of both normal and malignant hematopoietic cells [16,
40]. IL6 is released by monocytes, especially classical mono-
cytes, in response to ligation of various Toll-like receptors,
and therapeutic targeting of IL6/monocytes may therefore
be most effective for those patients with high levels of
classical monocytes.
Most of our patients received only 3 or 4 induction cy-
cles before stem cell transplantation, whereas 6 cycles
are now often recommended, especially for patients who
have not received a complete remission [25, 41, 42].
Alternative induction cycles have also been used in other
studies [33, 41, 42], and future studies have to clarify
whether our present results are representative also for
patients receiving additional cycles or alternative induction
treatment.
Fig. 3 The peripheral blood concentrations (a, upper part, n = 6) and percentages (b, lower part, n = 7) of total CD14+ monocytes and classical,
intermediate and non-classical monocyte subsets in auto-transplanted myeloma patients. Monocyte levels were estimated by flow cytometry. We
investigated the levels for a total of eight patients (Table 1, patients 15, 17, 18, 22–24) during initial hematopoietic and immunological
reconstitution (tested 10–12 days posttransplant) when the patients showed increasing neutrophils > 0.2 × 109/L and thrombocyte transfusion
independence). Horizontal lines indicate median values after 10–12 days. The shaded parts of each figure indicate the variation range of the
corresponding peripheral blood levels tested 2 days pre-transplant (referred to as day − 2), i.e. immediately before high-dose melphalan
conditioning therapy. Black symbols represent patients receiving their first auto-transplant, open symbols represent patients receiving their
second auto-transplantation
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Our comparison of induction treatments with and
without IMiDs suggests that the post-conditioning
monocyte concentrations are influenced by the previous
use of immunomodulatory drugs in the induction therapy,
whereas the capacity of stem cell mobilization and re-
sponse to the induction therapy are less important. How-
ever, G-CSF responsiveness (i.e. CD34+ cell mobilization)
was associated with the levels of intermediate and non-
classical monocytes before conditioning therapy.
Previous studies have shown that early posttransplant
lymphoid reconstitution is associated with a favorable
prognosis of auto-transplanted myeloma patients [26–29].
More recent studies suggest that this effect may be due to
early NK cell reconstitution [29]. Even though monocytes
have important immunoregulatory functions, the previous
studies have not investigated whether the early monocytic
reconstitution is required for the prognostic impact of
early lymphoid reconstitution. A recent study of allotrans-
plant recipients suggests that monocytes can mediate
anti-myeloma effects [43], and monocytes derived from
auto-transplanted patients may even be used for immuno-
therapy due to their presentation of myeloma-associated
peptides to the adaptive immune system [44]. Our present
studies thus suggest that a close to normal monocyte
system is present in myeloma patients even early after
auto-transplantation and may then be an immunothera-
peutic target.
Monocytes and macrophages are important members
of the bone marrow stem cell niches that support both
normal and malignant hematopoiesis [40]. IMiDs can
alter the differentiation of monocytes [24], and we there-
fore investigated whether the use of such drugs for
induction therapy was associated with an altered balance
between monocyte subsets later during treatment or
with other differences in hematopoietic reconstitution
between patients. Our present study showed that the
type of induction therapy actually has an influence on
monocytes/monocyte subsets, but this difference was
only detected after additional melphalan therapy in pre-
transplantation (Day 0) samples.
The observation time for our patients was relatively
short (27–35 months) for our patients that received their
first auto-transplantation and a majority of them were
still in a plateau phase. We could not detect any associa-
tions between time to progression (i.e. progression before
2 years posttransplant) and monocyte subset levels/recon-
stitution. However, these data should be interpreted with
great care because the patient cohort is relatively small for
such analyses and the observation time is short and
patients with early relapse are few.
Conclusions
Although our study is relatively small, we observed that
the total level of circulating monocytes is normalized
early after auto-transplantation for multiple myeloma.
However, the levels of various monocyte subsets show
considerable variation between patients. Clinical studies
including larger number of patients and a longer obser-
vation time are needed to clarify whether these differ-
ences are associated with overall survival, time to relapse
and/or frequencies of severe infections.
Methods
Aim, design, characteristics of myeloma patients and
healthy controls
Proteasomal inhibitors and IMiDs are now commonly used
in induction treatment of young and fit myeloma patients
prior to stem cell harvesting and auto-transplantation.
These drugs may thereby influence the pretransplant im-
munological status of the patients and the immunocompe-
tent cells in the stem cell graft. The aim of our present
study was therefore to investigate the preconditioning
status of the monocyte system in myeloma patients treated
with induction chemotherapy based on IMiDs or proteaso-
mal inhibitors, and to characterize the monocyte subset
levels in autotransplanted patients during the early post-
transplant period until hematological reconstitution.
Our hospital is the only center for stem cell trans-
plantation in a defined geographical area of Norway
(Health Region III), and our patients represent all
myeloma patients except one receiving autologous stem
cell transplantation in this area during an 8 months
period. Our study should therefore be regarded as a
population-based study of unselected patients.
The diagnosis of multiple myeloma was based on
generally accepted criteria [1, 45], and induction therapy
was initiated in accordance with generally accepted
international guidelines [45, 46]. The patient characteris-
tics are presented in Table 1. All patients received
premobilization therapy including either a proteasome
inhibitor or an IMiD; this induction treatment was
followed by stem cell mobilization using cyclophospha-
mide plus G-CSF [47, 48]. The stem cell grafts were
cryopreserved in 5% dimethyl sulfoxide and stored in
liquid nitrogen until reinfusion [49, 50]. All patients
were transplanted with at least 6 × 106 CD34+ cells per
kilo body weight, and the median time from start of
induction to transplantation was 16 weeks (range 13–28
weeks). For patients receiving their first auto-
transplantation the grafts had been stored for 3–5 weeks,
whereas for those patients receiving their second trans-
plantation the grafts were stored for at least 2 years. All
patients received conditioning therapy with melphalan
(Fresenius Kabi, Oslo, Norway), 200 mg/m2 administered
as an intravenous infusion 2 days before stem cell reinfu-
sion. They received G-CSF 5 μg/kg from day + 4 post-
transplant until stable neutrophil recovery, i.e. peripheral
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blood neutrophil levels above 0.2 × 109/L for three
consecutive days or exceeding 10 × 109/L.
The normal controls were healthy blood donors; in ac-
cordance with the approved routines at the Blood Bank,
Haukeland University Hospital peripheral venous blood
samples for medical research were donated after written
informed consent.
Blood sampling
Blood samples were drawn in ACD-A (9 mL, #248368,
BD Vacutainer, San Jose, CA, USA) blood sampling vac-
uum tubes. We collected the first patient sample imme-
diately before melphalan conditioning (day − 2). The
second sample was collected 2 days later immediately
before reinfusion of the peripheral blood stem cell graft
(day 0). The third sample was collected on day + 6 post-
transplant when patients had severe neutropenia (per-
ipheral blood neutrophil counts below < 0.2 × 109/L) and
thrombocytopenia. The last sample was collected on the
first or second day with peripheral blood neutrophil
counts exceeding 0.2 × 109/L (10–12 days posttrans-
plant). The control samples were derived from 17
healthy blood donors (5 females and 12 males, median
age 51 years with range 22–82 years). All samples were
processed at room temperature within 120 min. All
samples were collected between 08:00 and 10:00 am. It
was not possible to get samples from all patients at all
four time points; this was due to either transfer to their
local hospitals after stem cell reinfusion or the patient
was not available for sampling at the indicated time in
the morning.
Flow cytometric analysis
Four mL of ACD-A (9, #248368, BD Vacutainer) antic-
oagulated whole blood and 46 mL of lysing buffer (#
55589, BD Biosciences) were mixed and incubated for
15 min at room temperature. Subsequently, leukocytes
were collected by centrifugation (400×g, 5 min, room
temperature) and thereafter washed in phosphate-
buffered saline with 1% Bovine Serum Albumin (BSA,
Bovine Serum Albumin Fraction V #10735086001,
Sigma-Aldrich/Merc KGaA, Darmstadt, Germany),. The
cells were reconstituted in 200 μL 1% BSA/PBS with
10% immunoglobulin solution (Octagam 100mg/mL,
Octapharma, Lachen, Switzerland). The following mouse
anti-human antibodies were included in the antibody
panel (all from BD Biosciences, San Jose, CA, US): CD14
Alexa 488 (Clone M5E2), CD56 Alexa 647 (Clone B159),
CD16 PerCpCy™5–5 (Clone 3G8), CD45 V500 (Clone
HI30), CD11b V540 (Clone ICRF44 (44)) and HLA-DR
PE (Clone G46–6). The staining procedure and gating
strategy for identification of monocytes and monocyte
subsets has been described in detail in a previous
methodological article [37].
All samples were analyzed by a 10-parameter BD
FACS Verse flow cytometer equipped with 404, 488 and
640 nm lasers. We used BD FACSuite™ CS&T Research
Beads (#650621, BD Biosciences, San Jose, CA, USA) for
regular quality control of the instrument, single-stained
compensation bead samples (#552843, BD Biosciences)
for compensation and unstained samples as gating con-
trols. At least 5000 monocytes were analyzed for each
sample (based on SSC/FSC properties). We used count-
ing beads (Count Bright Absolute Counting beads™, #
C36950, Invitrogen™, Thermo Fischer Scientific, Waltham,
MA USA) when estimating the concentrations of mono-
cytes/monocyte subsets. FlowJo software (Tree Star, Inc.,
OR, USA) was used for analysis of the results.
Analysis of total leukocytes, neutrophils, monocytes and
thrombocytes in peripheral blood
Analyses of peripheral blood levels of total leukocytes
and total monocytes were performed by using accredited
clinical hematology instrument (Laboratory for Clinical
Biochemistry and Hematology at Haukeland University
Hospital).
Statistical analyses
We applied IBM SSP statistics 23 for all statistical ana-
lyses. The Wilcoxon’s rank sum test and the Wilcoxon’s
test for paired samples were used for comparison of dif-
ferent groups and for comparison of paired observations,
respectively. The Pearson’s test was used for correlation
analyses. Differences were regarded as statistically
significant when p-values were below 0.05.
Abbreviation
IMiDs: Immune modulatory drugs
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